Időskori makuladegeneráció: vizsgálatok itt: Kína
37 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- No phaseTaking peopleEffect of Video Viewing on Intravitreal Injection Experience
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 182
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07002372 - No phaseNot yet taking people in KínaAn Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings
- Where
- Guangzhou
- People
- 9999
- Run by
- Zhongshan Ophthalmic Center, Sun Yat-sen University
See details and how to joinNCT06918028 - Korai 1. fázisNot yet taking people in KínaTo Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)
- Where
- Xingtai, Yiwu
- Életkor
- 50 év and over
- People
- 8
- Run by
- Guangzhou Jiayin Biotech Ltd
See details and how to joinNCT06888492 - Korai 1. fázisTaking peopleCRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
- Where
- Shanghai, Tianjin
- Életkor
- 50 év to 80 év
- People
- 12
- Run by
- HuidaGene Therapeutics Co., Ltd.
See details and how to joinNCT06031727 - 2. fázisNot yet taking people in KínaEfficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD
- Where
- Beijing
- Életkor
- 50 év to 85 év
- People
- 40
- Run by
- Beijing Anlong Biopharmaceutical Co., Ltd.
See details and how to joinNCT06839339 - No phaseTaking peopleLong-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
- Where
- Beijing
- Életkor
- 50 év and over
- People
- 21
- Run by
- Beijing Anlong Biopharmaceutical Co., Ltd.
See details and how to joinNCT06718816 - 1/2. fázisTaking peopleSafety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
- Where
- Tianjin
- Életkor
- 50 év to 85 év
- People
- 44
- Run by
- Chengdu Origen Biotechnology Co., Ltd.
See details and how to joinNCT06458595 - 1/2. fázisTaking peopleSafety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
- Where
- Beijing
- Életkor
- 50 év to 85 év
- People
- 42
- Run by
- Chengdu Origen Biotechnology Co., Ltd.
See details and how to joinNCT05672121 - 1/2. fázisTaking peopleSafety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
- Where
- Tianjin
- Életkor
- 50 év and over
- People
- 48
- Run by
- Shanghai Refreshgene Technology Co., Ltd.
See details and how to joinNCT06141460 - 1/2. fázisTaking peopleGene Therapy(FT-003) for Wet AMD
- Where
- Tianjin
- Életkor
- 50 év to 80 év
- People
- 78
- Run by
- Frontera Therapeutics
See details and how to joinNCT06492863 - 1. fázisTaking peopleSafety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration
- Where
- Beijing
- Életkor
- 50 év to 75 év
- People
- 10
- Run by
- Beijing Tongren Hospital
See details and how to joinNCT05445063 - No phaseNot yet taking people in KínaObservation of the Natural Course of Age-related Macular Degeneration
- Where
- Shanghai
- Életkor
- 50 év to 85 év
- People
- 500
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT05418231